These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 34058994)
1. Increased serum concentration of netrin-1 after intravitreal bevacizumab injection: is it a compensatory mechanism to counteract drug side effects? Okutucu M; Fındık H; Aslan MG; Arpa M BMC Ophthalmol; 2021 May; 21(1):243. PubMed ID: 34058994 [TBL] [Abstract][Full Text] [Related]
2. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630 [TBL] [Abstract][Full Text] [Related]
3. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940 [TBL] [Abstract][Full Text] [Related]
4. Aqueous Levels of Angiopoietin-like 4 and Semaphorin 3E Correlate with Nonperfusion Area and Macular Volume in Diabetic Retinopathy. Kwon SH; Shin JP; Kim IT; Park DH Ophthalmology; 2015 May; 122(5):968-75. PubMed ID: 25687026 [TBL] [Abstract][Full Text] [Related]
6. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951 [TBL] [Abstract][Full Text] [Related]
7. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA; JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655 [TBL] [Abstract][Full Text] [Related]
8. Optical coherence tomography angiography analysis of macular vessel density before and after anti-VEGF therapy in eyes with diabetic retinopathy. Sorour OA; Sabrosa AS; Yasin Alibhai A; Arya M; Ishibazawa A; Witkin AJ; Baumal CR; Duker JS; Waheed NK Int Ophthalmol; 2019 Oct; 39(10):2361-2371. PubMed ID: 31119505 [TBL] [Abstract][Full Text] [Related]
9. Serum ischemia modified albumin and vascular endothelial growth factor levels following intravitreal bevacizumab injections. Soiberman U; Levy R; Schwartz S; Goldstein M; Loewenstein A; Barak A Eur J Ophthalmol; 2014; 24(4):570-5. PubMed ID: 24338577 [TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Sawada O; Kawamura H; Kakinoki M; Sawada T; Ohji M Arch Ophthalmol; 2007 Oct; 125(10):1363-6. PubMed ID: 17923544 [TBL] [Abstract][Full Text] [Related]
11. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Sohn HJ; Han DH; Kim IT; Oh IK; Kim KH; Lee DY; Nam DH Am J Ophthalmol; 2011 Oct; 152(4):686-94. PubMed ID: 21782151 [TBL] [Abstract][Full Text] [Related]
14. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456 [TBL] [Abstract][Full Text] [Related]
15. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy. Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145 [TBL] [Abstract][Full Text] [Related]
16. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Scott IU; Bressler NM; Bressler SB; Browning DJ; Chan CK; Danis RP; Davis MD; Kollman C; Qin H; Retina; 2008 Jan; 28(1):36-40. PubMed ID: 18185135 [TBL] [Abstract][Full Text] [Related]
17. Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy. Davidović SP; Nikolić SV; Curić NJ; Latinović SL; Drašković DO; Cabarkapa VS; Stošić ZZ Eur J Ophthalmol; 2012; 22(5):792-8. PubMed ID: 22344470 [TBL] [Abstract][Full Text] [Related]
18. Serological inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF. Brito P; Costa J; Gomes N; Costa S; Correia-Pinto J; Silva R J Diabetes Complications; 2018 Jul; 32(7):643-649. PubMed ID: 29843962 [TBL] [Abstract][Full Text] [Related]
19. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network. Krick TW; Bressler NM Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861 [TBL] [Abstract][Full Text] [Related]
20. Effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy. Chung EJ; Kang SJ; Koo JS; Choi YJ; Grossniklaus HE; Koh HJ Yonsei Med J; 2011 Jan; 52(1):151-7. PubMed ID: 21155048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]